UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Act of 1934
Date of Report (Date of earliest event reported): December 4, 2006 (November 28, 2006)
Zapata Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
(State or other jurisdiction
of incorporation)
|
|
001-4219
(Commission
File Number)
|
|
C-74-1339132
(I.R.S. Employer
Identification No.) |
|
|
|
100 Meridian Centre, Suite 350
Rochester, New York
(Address of principal executive offices)
|
|
14618
(Zip Code) |
(585) 242-2000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.133-4(c))
Item 2.01 Completion of Acquisition or Disposition of Assets
On November 28, 2006, Zapata Corporation, a Nevada corporation (Zapata) completed the sale
of 9,268,292 shares of common stock of Omega Protein Corporation, a Nevada corporation (Omega),
back to Omega pursuant to the terms and conditions of a Stock Purchase Agreement dated September 8,
2006 between Zapata and Omega, which was previously reported. The purchase price for the shares
was $5.125 per share, or $47,500,000 in the aggregate. Prior to the sale, Zapata owned
approximately 58% of Omega Proteins outstanding common stock, and immediately after completion of
the sale, owned approximately 33%. In connection with the closing, Zapatas two representatives,
Avram A. Glazer and Leonard DiSalvo, have resigned from Omegas Board of Directors.
The amount of the consideration was determined by arms length negotiations between Zapata and
Omega. The terms of the transaction were approved by an independent special committee of Omegas
Board of Directors which did not include either Mr. Glazer or Mr. DiSalvo. In addition, the Omega
special committee received the opinions of TM Capital Corp., an independent financial advisor,
regarding the fairness, from a financial point of view, of the purchase price to Omegas
stockholders (except for Zapata), and the solvency of Omega following the consummation of the
transactions. TM Capital provided Zapata with a reliance letter allowing it to rely on the
solvency opinion.
The terms of the transaction were also approved by Zapatas Board of Directors and by the
written consent of the holder of a majority of the outstanding shares of Zapatas common stock.
Zapatas Board of Directors received the opinion of Empire Valuation Consultants, LLC, an
independent financial advisor, regarding the fairness, from a financial point of view, to Zapatas
stockholders of the purchase price and the transaction.
A copy of the press release announcing the closing is attached hereto as Exhibit 99.1.
Item 9.01 Exhibits
|
99.1 |
|
Press Release Dated November 28, 2006 |
-2-